Pharmicell signs MoU with India’s ILBS to jointly develop stem cell therapy
- by Team ABLE - 15 Feb, 2019
Pharmicell, a Korean developer of human stem cell therapies, has signed a memorandum of understanding with India-based Institute of Liver and Biliary Sciences(ILBS) for joint clinical research and business cooperation.
Under the agreement, the two will jointly conduct clinical studies to develop a stem cell therapy to treat liver disease, while Pharmicell will share its know-how with ILBS in the establishment and operation of GMP facilities to produce stem cell therapies in India.The two aim to strengthen basic research, develop and commercialize next-generation stem cell therapies across India.
Dr. Shiv Kumar Sarin, a key researcher of ILBS and authority in hepatology, will be involved in the joint clinical research with Pharmicell.
Under the agreement, the two will jointly conduct clinical studies to develop a stem cell therapy to treat liver disease.